SCARA3

Across TCGA pan-cancer cohorts, SCARA3 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SCARA3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SCARA3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SCARA3 is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

LUAD and HNSC are the cancer types where SCARA3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SCARA3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	II,III,IV	−0.558	<.001	8	view →
HNSC	All	IV	−0.330	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

SCARA3–LUAD

Open the LUAD breakdown →